Dyslizet 10 mg (ezetimibe)

Dyslizet is a pharmaceutical product containing the active ingredient ezetimibe, used primarily to lower cholesterol levels. The brand is managed by Viatris, a global healthcare company formed through the merger of Mylan and Pfizer's Upjohn division. Manufacturing for Viatris products occurs across a vast network of facilities worldwide, often including locations in Ireland, India, and the United States, depending on the specific supply chain for the regional market.

The product is part of Viatris's extensive portfolio of generic and branded medicines. Headquartered in the United States, Viatris operates globally, providing essential medications across various therapeutic areas. In Italy, where this specific packaging is distributed, it is managed through their local corporate subsidiary.